Cannatrek has signed a multi-year supply agreement to export dried cannabis flowers to German-based Nimbus Health.
The Australian medicinal cannabis producer will supply an initial 200 kgs to Nimbus, with the potential to increase to larger commercial quantities as distribution channels are established across Germany and other European regions.
The first batch of Cannatrek’s dried flowers is planned for shipment in the first half of 2021 and will be used in a range of medicines to treat pain, anxiety, sleep disorders and depression.
Cannatrek CEO Tommy Huppert said the move represents a significant step in the company’s growth plans and a sign of the growing popularity of Australian product.
“We are thrilled to be supplying such an important German partner, which gives us a toehold in the large European market. Cannatrek’s brand will arrive in Europe early next year.”
“Australia is a great place to grow medicinal cannabis because of its ample, hot sun that produces excellent terpene profiles and quality products.”
Cannatrek’s German exports will be delivered via vaporization inhaler.
“Vaporizers heat the flowers, and the inhaled vapour creates an instant therapeutic effect for managing the relief of breakthrough pain and other medical symptoms,” added Huppert.
Nimbus Health is a global pharmaceutical company that imports and distributes medicinal cannabis
Prohibition Partners predicts the German medical cannabis market will be worth A$12.5 billion by 2028.
